Molecular Analysis for Therapy Choice (MATCH)
- Result Type
- clinical trial
This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas.
Status: Active, Recruiting
7results found for:
Androgen Deprivation Therapy and High Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer A Phase III Randomized Trial
- Result Type
- clinical trial
This randomized phase III trial studies androgen-deprivation therapy and radiation therapy in treating patients with prostate cancer.
Status: Active, Recruiting
Phase II-III Trial of Adjuvant Radiotherapy Following Radical Prostatectomy With or Without Adjuvant Docetaxel
- Result Type
- clinical trial
This randomized phase II/III trial studies docetaxel, antiandrogen therapy, and radiation therapy to see how well it works compared with antiandrogen therapy.
Status: Active, Recruiting
Phase Ib/II Trial of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-365)
- Result Type
- clinical trial
Purpose of this study is to assess the safety and efficacy of pembrolizumab combination therapy in patients with metastatic castrate resistant prostate cancer.
Status: Active, Recruiting
TRITON2: A Multicenter, Open-label Phase 2 Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency
- Result Type
- clinical trial
The purpose of this study is to determine how patients with metastatic castration-resistant prostate cancer respond to treatment with rucaparib
Status: Active, Recruiting
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone
- Result Type
- clinical trial
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of ipatasertib plus abiraterone and prednisone/prednisolone.
Status: Active, Recruiting
A Study of Atezolizumab (Anti-PD-L1 Antibody) in Combination With Enzalutamide in Participants With Metastatic Castration-Resistant Prostrate Cancer After Failure of an Androgen Synthesis Inhibitor
- Result Type
- clinical trial
This Phase III, multicenter, randomized, open-label study will evaluate the safety and efficacy of atezolizumab (anti-programmed death-ligand 1 antibody)
Status: Active, Recruiting